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ANTIBIOTIC USE DURING PREGNANCY AND NEURODEVELOPMENTAL  
 
OUTCOMES OF OFFSPRING IN EARLY CHILDHOOD 
 
TRESSA GAMACHE 
 
ABSTRACT 
There is limited research on the effects of antibiotic use during pregnancy on 
neurodevelopmental outcomes of offspring in early childhood. The aim of this study was 
to investigate associations between antibiotic use during early pregnancy and 
neurodevelopmental outcomes, both behavioral and cognitive, in the offspring during 
early childhood. This thesis examined a longitudinal study of 570 mother-child pairs 
where prenatal exposures and at least one neurodevelopment outcome assessment were 
recorded. An interview was conducted with mothers on average one year after delivery to 
collect information on prenatal exposures. Neurodevelopmental outcomes were assessed 
between the ages 5–11 years using the cognitive-based outcomes of Peabody Picture 
Vocabulary Test (PPVT-III) and the Beery-Buktenica Test of Visual Motor Integration-
Fifth Edition (VMI-5) and behavioral-based outcomes of the Child Behavior Checklist 
(CBCL) and Teacher Report Form (TRF). Adjusted mean differences (adjMD) in 
outcome measures were calculated between mothers reporting antibiotics use and 
mothers reporting treated infections. Antibiotic use during pregnancy was not 
significantly associated with the two cognitive measures but was associated with 
increased total behavioral problems reported by mothers (adjMD: 2.60; CI: 0.50, 4.69) 
and teachers (adjMD 2.60; 95% CI 0.44, 4.76). Overall, antibiotics use during pregnancy 
was not associated with differences in childhood cognition but may be associated with 
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greater behavior problems.  
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Antibiotic Use During Pregnancy and Neurodevelopmental Outcomes of Offspring in 
Early Childhood 
Over the course of pregnancy, there are dramatic changes in the composition of 
the maternal gut microbiota which influences the long-term health of both mother and 
child (Cenit, Sanz, & Codoñer-Franch, 2017). The gut microbiota is considered a 
regulator along the gut-brain axis and maternal gut microbiota may play a key role in 
neurodevelopment and neurodegenerative disorders of offspring (Cenit, Sanz, & 
Codoñer-Franch, 2017). Antibiotic use during pregnancy profoundly affects maternal 
microbiota which shapes the microbial colonization of the infant gastrointestinal tract of 
the fetus (Gonzalez-Perez, et al., 2016). Therefore, with side effects known to disrupt the 
microbiome, antibiotics may in turn have effects on this gut-brain axis and consequently, 
also affect neurodevelopment. 
Antibiotics are beneficial and relatively safe during pregnancy with 
approximately 8% to 20% of women being prescribed antibiotics during pregnancy 
(Amann, et al., 2006; Czeizel, et al., 1998; Headley, et al., 2004). Antibiotic treatment 
accounts for 80% of prescribed medications during this period (Kuperman & Koren, 
2016; Landers, et al., 1983; Mitchell, et al., 2011). Despite the frequency of antibiotic use 
during pregnancy and likely effects of antibiotics on the gut-brain axis of both the mother 
and fetus, there has been limited research on outcomes related to prenatal exposure to 
antibiotics (Czeizel, et al., 1998; Cenit, Sanz, & Codoñer-Franch, 2017). 
One study of antibiotic use during pregnancy has suggested an association with 
increased incidence of autism spectrum disorder (ASD) in the offspring. This study 
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examined the association between prenatal antibiotic exposure and ASD when the 
children were between 8–14 years of age. The study found that there was an 
approximately 40–60% increased risk of ASD with use of sulfonamides any time during 
pregnancy and penicillin during the second or third trimesters (Atladóttir, et al., 2012).  A 
population-based cohort study in Canada that began in April 1998 did a similar analysis 
looking at the effect of any antibiotic exposure prenatally on the risk of ASD in children 
of at least 18 months of age. The results from this analysis showed an increased risk of 
ASD (HR 1.11) for children who had prenatal exposure to antibiotics (Hamad, et al., 
2019). 
There is also additional research that supports effects on the gut-brain-axis 
resulting in neurodevelopmental changes when looking at prenatal infections. A recent 
study examined the effects of bacterial infections during pregnancy on cognitive 
performance in early childhood. This study found that bacterial infections during 
pregnancy, especially later during pregnancy, were associated with lesser IQ scores in 
children by the age of 7 years old (Lee, et al., 2020).  A meta-analysis of 10 studies was 
also conducted to assess the association of maternal chorioamnionitis (MC), a common 
infection of pregnancy, and neonatal motor development in preterm infants. This analysis 
found the pre-term infants of mothers who had MC had poorer mental and motor 
developments than those who had not been exposed to MC (Xiao, et al., 2018). 
The limitations of the prior research pose a challenge in determining whether 
there is an association between prenatal exposure antibiotics and long-term effects on 
neurodevelopment. In addition, these studies examined an exposure of prenatal 
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antibiotics use or prenatal infections resulting in a lack of understanding whether there 
was an interaction that exists between the two exposures. The prior research is also 
limited in making broad characterizations of the association between maternal antibiotics 
use and subsequent child neurodevelopment due to restrictions in exposure and outcome 
variables such as exposures of MC versus all infections or outcomes of ASD rather than 
broad neurodevelopment categories. Due to the cost of lengthy follow ups and likelihood 
of participant attrition, most studies conducted on in utero exposures were limited to 
outcomes that were detectible during infancy. For outcomes that can take years to 
develop, such as more complex behavior or other developmental measures, early life 
outcomes that occur during infancy will not suffice. 
The current study aims to increase the understanding of prenatal antibiotic use and 
long-term neurodevelopment outcomes of the offspring to fill these gaps in current 
research. Additional research in this area is important to provide more informed 
prescribing guidance to pregnant women on possible long-term side effects for their 
children exposed in utero. At present, older antibiotics are grandfathered in as safe due to 
limited short-term outcomes and new antibiotics are not tested on pregnant women due to 
potential ethical concerns. Observational research on long-term effects on the fetus is 
required to add to the body of literature to support the safety of this at-risk population. 
Study Design 
 This study is examining the cognitive and behavioral outcomes of children who 
previously participated in a multicenter, case-control study of risk factors for hemifacial 
microsomia (HFM). This analysis will be restricted to the controls of this study 
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population, or children without malformations. The study received approval from 
institutional review board at Boston University and was completed in compliance with 
the Health Insurance and Accountability Portability Act (HIPAA) standards. 
Study subjects 
 The identification of controls (child-mother pairs) has been previously published 
(Werler, et al., 2004; Collett, et al., 2011). In short, controls were identified through 
community pediatrician’s in the vicinity of the 26 enrolling craniofacial centers across the 
United States and Canada. To be eligible, the controls were less than 4 years old, not 
adopted, and had no major malformations. Participants completed a standardized 
interview that collected data on demographics, reproductive history, and pregnancy 
exposures, including medications.  Mothers of children were subsequently approached 
when the child was between 5 and 11 years of age to assess childhood neurodevelopment. 
Of the 826 controls that were eligible, 570 completed at least one of the childhood 
neurodevelopmental assessments. 
Study Measurements 
Antibiotic Use 
Antibiotic use during early pregnancy (started within five months of her last 
menstrual period) is the primary exposure of interest. Illnesses and medication use were 
self-reported by the mother during the initial interview that took place within an average 
of 47 months of giving birth. The mother was prompted with a calendar of a six-month 
time period that began 1 month prior to her last menstrual period and ended 5 months 
after her last menstrual period based on the date of birth provided in order to focus 
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recollection to the timeframe of interest. 
Medication use was obtained in two ways. First, medication use was captured 
indirectly by asking participants about illnesses that occurred during the six-month time 
period and then would subsequently be asked about medications to treat any reported 
illness. In this interview, participants were specifically asked about upper respiratory 
infection (URI) and sinusitis/sinus headache which were most pertinent for subsequent 
antibiotic use. Medication use was also directly ascertained through a prompted review of 
a medication list divided into 11 major drug categories, antibiotics being one of these 
categories. If the mother confirmed use, they would be requested to gather the bottle or 
prescription, if available, to provide further details on the medication. In any case of 
reported medication use, the mother was asked to provide additional information 
including diagnosis, start and stop date, frequency and dosage. Medications included in 
the medications list were classified based on active ingredient or class using the Boston 
University Slone Drug Dictionary, a computerized coding system that includes codes for 
prescription and non-prescription drugs, dietary supplements, and other natural products 
(Boston University Slone Epidemiology Center Slone Drug Dictionary). 
For the purpose of this analysis, the exposed group is children of mothers with 
any reported antibiotic use during early pregnancy. The reference group for all analyses 
will be children of mothers who did not report antibiotic use during early pregnancy. 
Neurodevelopmental Outcomes 
The neurodevelopmental outcomes of the offspring were measured by four 
different assessments. These assessments included the Peabody Picture Vocabulary Test-
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Third Edition (PPVT-III), the Beery-Buktenica Development Test of Visual Motor 
Integration-Fifth Edition (VMI-5), the Child Behavior Checklist (CBCL) and Teacher 
Report Form (TRF). The PPVT-III and VMI-5 focused on cognitive-based outcomes 
while the CBCL and TRF focused on behavior-based outcomes. 
The PPVT-III is a norm-referenced measure of receptive vocabulary. Respondents 
were presented with increasingly difficult vocabulary words and shown four target 
pictures. They were asked to point to the picture that represents the word. Reliability is 
excellent, and convergent validity is supported by strong correlations with other measures 
of verbal ability and prediction of academic achievement (Dunn & Dunn, 1997). Higher 
scores on this test indicate better receptive vocabulary in the child. 
Perceptual-motor skills were measured by the Beery-Buktenica Test of Visual 
Motor Integration-Fifth Edition (VMI-5). The VMI-5 is a norm-referenced measure of 
perceptual motor abilities. Respondents copy a series of 24 increasingly difficult 
geometric designs which were scored for accuracy by an examiner. The VMI-5 has good 
reliability, including strong test-retest stability and inter-scorer reliability among diverse 
examiners (e.g., ranging from psychologists to teachers). Validity of the VMI-5 is 
supported by convergence with other measures of visual perception and low correlations 
with verbal measures (Beery, Buktenica, & Beery, 2004). Higher scores indicate better 
perceptual motor abilities. 
Mothers and teachers completed the Child Behavior Checklist (CBCL) and 
Teacher Report Form (TRF), respectively. These instruments were widely used in 
psychiatric research and with similar item content between tests, it allows for a 
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systematic comparison of child behavior. Both measures provide summary composite 
scales of internalizing behavior problems, externalizing behavior problems and total 
behavior problems. For these analyses, the total behavior problem scale was used across 
the two measures. T-scores were calculated for the total behavior problem scale on each 
test with a mean of 50 and an SD of 10. Both measures have well-established reliability 
and validity (Achenbach & Rescorla, 2001). Higher scores indicate greater behavioral 
problems. 
Statistical Analyses 
Demographic variables were summarized using frequencies and appropriate 
summary statistics. The summary statistics were presented based on exposure groups 
(antibiotic use or no antibiotic use). Demographic variables include maternal race, age, 
education, household income, marital status, region of the country, pre-pregnancy BMI, 
smoking status during pregnancy, and drinking status during pregnancy. 
Antibiotic use was summarized by individual antibiotic and class of antibiotics. 
Due to limited samples size in antibiotic categorizations, the antibiotic categorizations 
will be presented as descriptive statistics only and will not be further analyzed for 
associations with the outcome. 
Following identification of those exposed to antibiotics, diagnoses relating to their 
exposures were reviewed and categized by type, upper respiratory infection (URI), 
urogenital infection (UGI), or indications that were not typical of antibiotic use. 
Indications that were included with the URI categorization include pharyngitis 
streptococcal, otitis not otherwise specified (NOS), earache, common cold, acute 
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sinusitis, acute bronchitis, asthma, upper respiratory symptoms, and cough. Indications 
that were included with the UGI categorization include beta strep infection, kidney 
infection, cystitis, urinary tract infection, vaginitis, genital infection NOS, and vaginal 
bleeding. Indications that were included in the not applicable grouping included pain 
NOS and acne. Since this grouping of indications were inherently outliers, they were 
dropped from all analyses. The categorizations of URI and UGI were also combined to 
look at effects of any infection. Once these categorizations were determined using the 
above indications in the exposed group, they were then applied to the unexposed group 
Average mean scores on the cognitive tests, PPVT-III and VMI-5, and the 
average total behavior problems T-score on the behavior assessment tools, CBCL and 
TRF, were calculated for children exposed and unexposed to antibiotics prenatally.  
An adjusted linear regression model was used to calculate adjusted mean 
difference (MD) and 95% confidence interval (CI) for exposed versus unexposed using 
children unexposed to antibiotics prenatally as the reference.  Potential confounders were 
identified theoretically and included maternal race, age, education, region of the country, 
pre-pregnancy BMI, smoking status during pregnancy, drinking status during pregnancy, 
URI, UGI and any infection. 
In addition to the primary analysis, a secondary analysis was completed restricting 
the population to only those mothers who reported infection. Utilizing an adjusted linear 
regression model the analysis examined the effect of infections during pregnancy treated 
with antibiotics versus those left untreated on neurodevelopmental outcomes in the 
children of those mothers during early childhood.  Analyses were performed using SAS 
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Software Version 9.3 and the GLM procedure (SAS Institute, Cary, NC). 
Results 
Cohort characteristics 
Maternal characteristics of children exposed and unexposed to antibiotic use 
during early pregnancy are shown in Table 1. Of the 570 mother-child pairs included in 
this analysis, approximately 19% (n=111) reported antibiotic use in early pregnancy. 
Antibiotic users were more likely to be white/non-Hispanic mother (82% compared to 
74.1% among the unexposed), obese (18.9% compared to 10.6%), and smokers (18.9% 
compared to 15.0%).  
A total of 361 mothers reported indications relating to infections during early 
pregnancy across this population, with 103 women treating them with antibiotics. In the 
exposed group 78.4% reported indications relating to URI and 35.1% relating to UGI vs. 
49.7% and 13.6%, respectively, in the unexposed group. There were 8 reports of 
antibiotics use with no accompanying infection-related diagnosis. The indications 
reported included cornea abrasion (n=2), infection prophylaxis (n=2), calculus kidney, 
pain not otherwise specified, bleeding gums and dental surgical operation not otherwise 
specified. 
Exposure characteristics 
Antibiotic use was reported 131 times across the 111 subjects exposed. Fifteen 
mothers reported more than one incidence of antibiotic use during early pregnancy. The 
median length of use per incident was 7 days with a minimum length of 1 day and 
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maximum length of 280 days. Frequency of reported use by antibiotic class is described 
in Table 2. 
Primary Analysis 
The results of the adjusted multivariable regression analyses assessing the 
relationship between maternal antibiotic use during pregnancy and neurodevelopmental 
outcomes in the offspring are presented in Table 3.  Antibiotic use during early 
pregnancy was associated with mixed associations across the neurodevelopmental 
measures. Within the cognitive outcomes, those children exposed to antibiotics in utero 
had PPVT-III scores 1.12 points better than those unexposed (adjMD 1.12; 95% CI -1.89, 
4.13) indicating better receptive vocabulary in those exposed, but VMI-5 scores 0.48 
points worse than those unexposed (adjMD -0.48; 95% CI -2.90, 1.93) indicating worse 
perceptual motor abilities in those exposed. Confidence intervals around these 
associations were wide indicating a lack of precision and included the null value. Within 
the behavioral outcomes, those exposed had TRF scores 2.60 points greater than those 
unexposed (adjMD 2.60, 95% CI 0.50,4.69) indicating worse behavioral problems as 
reported by the teacher in those exposed and CBCL scores 2.60 points worse than those 
unexposed (adjMD 2.60; 95% CI 0.44, 4.76) indicating worse behavioral problems as 
reported by the mother in those exposed. Both associations also had wide confidence 
intervals indicating a lack of precision, however, the intervals did not include the null 
value. 
To address confounding by indication, the regression models were also adjusted 
by URI, UGI and any infection. When adjusting for URI, mean differences for PPVT-III 
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and VMI-5 scores were strengthened, however, remained directionally opposite and with 
wide confidence intervals including the null value. Those exposed had PPVT-III scores 
1.37 better than those unexposed (adjMD 1.37, 95% CI -1.70, 4.43), but VMI-5 scores 
0.77 points worse than those unexposed (MD 0.77; 95% CI -3.23, 1.67). In this model, 
the mean differences for TRF and CBCL were reduced compared to the demographic 
adjusted mean differences. Those exposed had TRF scores 2.06 worse (adjMD 2.06, 95% 
CI -0.08, 4.21) and CBCL scores 1.66 points worse (adjMD 1.66; 95% CI -0.54, 3.86) 
than those unexposed. When adjusting for UGI, the mean difference for PPVT-III was 
greatly reduced compared to both the demographic and URI adjusted models so while 
still showing better receptive vocabulary in those exposed, the magnitude was greatly 
reduced with those exposed having PPVT-III scores 0.72 points better than those 
unexposed (adjMD 0.72; 95% CI -2.39, 3.84). There was very little change in the mean 
differences for VMI-5 and CBCL from the demographic adjusted model. Those exposed 
had VMI-5 scores 0.50 points worse (adjMD -0.05, 95% CI -2.99, 2.00) and CBCL 
scores 2.58 points worse than those unexposed (adjMD 2.58, 95% CI 0.35, 4.81). After 
adjusting for UGI, the mean difference for TRF scores increased, showing a greater 
magnitude in the behavior problems as reported by the teacher in those exposed, 
compared to demographic and URI adjusted models. Those exposed had TRF scores 3.31 
points worse than those unexposed (adjMD 3.31; 95% CI 1.16, 5.47). Lastly, after 
adjusting for any infection, the mean differences for PPVT-III, TRF, and CBCL scores 
were consistent with the demographic and URI adjusted models. The mean difference for 
VMI-5 scores, however, is increased showing worsened perceptual motor abilities in 
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those exposed compared to the demographic and URI adjusted models with those 
exposed having VMI-5 scores 1.06 points worse than those unexposed (adjMD -1.06, 
95% CI -3.56, 1.44). Overall, there is a consistency through the crude, demographic, URI 
and UGI adjusted models that those exposed have better PPVT-III scores indicating 
better receptive vocabulary, but worse VMI-5, CBCL and TRF scores indicating worse 
perceptual motor abilities and behavioral problems as reported by the mother and teacher, 
respectively, than those unexposed.  
Secondary analyses 
The results of the adjusted multivariable regression analyses restricted to only 
those mothers reporting infections during pregnancy to assess the relationship between 
treated infections during pregnancy and neurodevelopmental outcomes in the offspring 
with untreated infections as the reference group are presented in Table 4 
After restricting to only those mothers with any reported infection-related 
diagnosis during early pregnancy, the effects of antibiotic use on the neurodevelopmental 
outcomes of their offspring in early childhood remain similar to the unrestricted analyses 
adjusted by any infection presented in Table 3. Although results had wide confidence 
intervals indicating a lack of precision, children whose mothers had treated infections 
during early pregnancy had PPVT-III scores better than those unexposed, while having 
worse scores across VMI, TRF and CBCL assessments consistent with the unrestricted 
primary analyses. Those exposed had PPVT-III scores 1.90 points better (MD 1.90; 95% 
CI -1.48, 5.28), but VMI-5 scores 0.98 points worse (MD -0.98; 95% CI -3.64, 1.68), 
CBCL scores 2.05 points worse (MD 2.05, 95% -0.28, 4.39), and TRF scores 1.92 points 
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worse (MD 1.92, 95% CI -0.47, 4.31) than children whose mothers had infections that 
were not treated during early pregnancy. 
Differences in neurodevelopmental scores in children whose mothers reported 
treated URI related diagnoses during early pregnancy were directionally consistent with 
the model for any infection, however, found greater differences in magnitude across all 
measures than those differences found in the unrestricted analyses adjusted by URI 
presented in Table 3. When restricting to treated URI related diagnoses during early 
pregnancy, children whose mothers were treated had PPVT-III scores 3.10 better (MD 
3.10; 95% CI -0.61, 6.81), but VMI-5 scores 1.03 points worse (MD -1.03; 95% CI -3.96, 
1.90), CBCL scores 2.01 points worse (MD 2.01, 95% -0.55, 4.58), and TRF scores 2.28 
points worse (MD 2.28, 95% CI -0.30, 4.87) than children whose mothers were untreated. 
Among those children who mothers had treated UGI related diagnoses during 
early pregnancy, there was an inconsistency in the associations found compared to those 
associations presented in the unrestricted analyses adjusted by UGI in Table 3. The mean 
difference for PPVT-III was directionally opposite from the rest of the models with 
children of mothers who reported a treated UGI related diagnosis during early pregnancy 
having a PPVT-III score 3.42 points worse than those children whose mothers were 
untreated (MD -3.42, 95% -8.77, 1.92) indicating worse receptive vocabulary in those 
children of treated mothers. The mean VMI-5 scores were also directionally opposite 
from the rest of the models with children of mothers who reported a treated UGI during 
early pregnancy having VMI-5 scores 1.22 points better than those children whose 
mother reported an untreated UGI during early pregnancy (MD 1.22; 95% CI -3.52, 
  
 
 
14  
 
5.97). While the mean differences for CBCL and TRF scores remain directionally 
consistent with the unrestricted UGI adjusted analysis, the mean difference for TRF 
scores is much less in magnitude comparatively. Those exposed had CBCL scores 3.45 
points worse than those unexposed (adjMD 3.45; 95% CI -0.36, 7.26) and TRF scores 
0.95 points worse than those unexposed (adjMD 0.95; 95% CI -3.63, 5.53). 
Overall, results across the any infection and URI restricted analysis found 
consistent results and were also consistent with the unrestricted analysis, however, the 
UGI restricted model emerged with some inconsistent results. The any infection and URI 
restricted analysis found that those treated had children with better PPVT-III scores, but 
worse VMI-5, CBCL, and TRF scores. For the UGI restricted analysis, children of  
treated mothers had better VMI-5 scores, but worse PPVT-III, CBCL and TRF scores 
indicating better perceptual motor abilities, but worse receptive vocabulary and behavior 
problems as reported by the mother and teacher, respectively. Results from these analyses 
have wide confidence intervals indicating a lack of precision. 
Discussion 
The results of these analyses showed a consistent trend that prenatal antibiotic 
exposure was associated with greater childhood behavioral problems as indicated by the 
increases in CBCL and TRF scores. Mean CBCL and TRF scores across exposed and 
unexposed groups remain below the borderline and clinical T-score cut-offs so while 
those exposed have higher scores they do not indicate clinical intervention (Achenbach & 
Rescorla, 2001). Associations of prenatal exposure to antibiotics and cognitive outcomes, 
PPVT-III and VMI-5, were less consistent. Children with prenatal antibiotic exposure 
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had higher PPVT-III scores indicating better receptive vocabulary, but lower VMI-5 
scores indicating worse perceptual motor abilities than those unexposed.  
After adjusting the primary analysis by overall infection, URI and UGI, trends 
maintained the same direction with some small differences in magnitude. Similar results 
were also seen in the secondary restricted analyses, however, in the UGI restricted model, 
both PPVT-III and VMI had directionally inconsistent results with the rest of the primary 
and secondary analyses. The incidence of UGI in this sample is much less compared to 
URI so the primary analysis results of URI and any infection were more similar than 
those of UGI. Due to the limited sample of UGIs, firm conclusions cannot be drawn from 
the UGI restricted model as the inconsistent results may be due to variability. 
With the ability to follow up with the same mother-child pairs of the original 
study, we’re able to examine in utero exposure with long term neurodevelopmental 
outcomes. Mothers were asked to recall use of antibiotics and illness after delivery which 
may have resulted in exposure misclassification, although the interview was standardized 
and the average time between delivery and the interview was 1 year.  Additionally, the 
CBCL was completed via the mother’s report and if the mother had difficulty with recall 
of antibiotics, it’s possible that she also had a poor assessment of her child’s behavior 
creating dependent misclassification. Since we also have the teacher’s assessment of the 
child’s behavior via the TRF we were able to obtain feedback on the outcome without 
influence or knowledge of the exposure and results were similar. 
Since antibiotic use and neurodevelopmental outcomes were not the primary 
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purpose of the original study design, there were limitations in the collection of these data. 
Antibiotics, and more generally medications, were collected up until six months after the 
mother’s last menstrual period. Therefore, most of these data were restricted to the first 
two trimesters of pregnancy reducing any conclusions drawn to be restricted to early 
pregnancy. Diagnoses based on medication use were also prompted responses within the 
interview with URI being one of these categories. This provided the opportunity to an 
overreporting of URI and potential underreporting of other indications that were not 
prompted responses, like UGI, which causes limitations in drawing conclusions across 
these groups. Also due to the prompted responses, antibiotic use was closely linked with 
occurrence of infection, especially URI, making it difficult to distinguish associations 
with the outcomes due to antibiotics versus infections. The sample size is also limited 
which increases variability ultimately making it difficult to show statistical significance 
and draw strong conclusions but will add to the body of literature to help identify 
potential associations. Additionally, since we were limited in the number exposed, we 
were unable to do further associations by grouping the antibiotics by class or FDA risk 
categorization which may have better results given all antibiotics do not interact with the 
body in the same manner. Overall, this study, even with its limitations, should help bring 
to light potential safety risks in using antibiotics during pregnancy and support the risk 
benefit analysis required when prescribing these medications to pregnant women. 
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Tables 
Table 1 
Maternal characteristics during pregnancy of children exposed and unexposed 
Characteristic 
Exposed 
(n=111) 
Unexposed 
(n=459) 
 n % n % 
Maternal Race 
White/Non-Hispanic 
Hispanic 
Black 
Other 
 
91 
8 
10 
2 
 
82.0% 
7.2% 
9.0% 
1.8% 
 
340 
59 
39 
21 
 
74.1% 
12.9% 
8.5% 
4.6% 
Maternal Age 
<25 years  
25–34 years 
≥ 35 years 
 
16 
76 
19 
 
14.4% 
68.5% 
17.1% 
 
99 
282 
78 
 
21.6% 
61.4% 
17.0% 
Maternal Education 
<12 years 
12-15 years 
≥ 15 years 
 
30 
30 
51 
 
27.0% 
27.0% 
46.0% 
 
142 
106 
211 
 
30.9% 
23.1% 
46.0% 
Family Income 
≤$15,000 
$15,001-$25,000 
$25,001-$35,000 
$35,001-$65,000 
>$65,000 
Missing 
 
9 
9 
7 
41 
41 
4 
 
8.1% 
8.1% 
6.3% 
36.9% 
36.9% 
3.6% 
 
38 
36 
61 
138 
160 
25 
 
8.3% 
7.9% 
13.3% 
30.1% 
34.9% 
5.5% 
Marital Status 
Married 
Other 
 
85 
26 
 
76.6% 
23.4% 
 
361 
98 
 
78.7% 
21.4% 
Region 
Northeast 
Mid-Atlantic 
Midwest 
South 
West 
 
16 
13 
36 
22 
23 
 
14.6% 
11.8% 
32.7% 
20.0% 
20.9% 
 
78 
50 
131 
68 
131 
 
17.0% 
10.9% 
28.6% 
14.9% 
28.6% 
Pre-pregnancy BMI 
<18.5 
18.5-24.9 
25-29.9 
30+ 
 
6 
66 
18 
21 
 
5.4% 
59.5% 
16.2% 
18.9% 
 
13 
293 
99 
48 
 
2.9% 
64.7% 
21.9% 
10.6% 
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Characteristic 
Exposed 
(n=111) 
Unexposed 
(n=459) 
 n % n % 
Smoking Status 
No 
Yes 
 
90 
21 
 
81.1% 
18.9% 
 
390 
69 
 
85.0% 
15.0% 
Drinking Status 
No 
Yes 
 
102 
9 
 
91.9% 
8.1% 
 
412 
47 
 
89.8% 
10.2% 
Any Infection 
No 
Yes 
 
8 
103 
 
7.2% 
92.8% 
 
201 
258 
 
43.8% 
56.2% 
Upper Respiratory Infection (URI) 
No 
Yes 
 
24 
87 
 
21.6% 
78.4% 
 
230 
227 
 
50.3% 
49.7% 
Urogenital Infection (UGI) 
No 
Yes 
 
72 
39 
 
64.9% 
35.1% 
 
395 
62 
 
86.4% 
13.6% 
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Table 2 
Frequency of antibiotics used by class 
Antibiotic Class Frequency 
 n % 
Ampicillin 42 32.1% 
Sulfonamide 3 2.3% 
Tetracycline 3 2.3% 
Cephalosporin 18 13.7% 
Macrolides 20 15.3% 
Penicillin 6 4.6% 
Other antibiotics 40 30.5% 
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Table 3 
Mean difference in neurodevelopmental test scores of children among mothers who used antibiotics compared to those that did 
not antibiotics during early pregnancy 
 
Test N Mean (SD) Mean Difference (95% CI) 
 
Antibiotic 
Use 
No 
Antibiotic 
Use 
Antibiotic Use 
No Antibiotic 
Use 
Crude Adjusted 
Adjusted for 
Any Infection 
Adjusted for 
URI 
Adjusted for 
UGI 
PPVT-III 92 377 107.75 (13.60) 105.92 (14.39) 
1.83 
(-1.43, 5.08) 
1.12 
(-1.89, 4.13) 
1.56 
(-1.59, 4.70) 
1.37 
(-1.70, 4.43) 
0.72 
(-2.39, 3.84) 
VMI-5 92 376 96.22 (10.43) 96.83 (10.77) 
-0.61 
(-3.01,1.79) 
-0.48 
(-2.90, 1.93) 
-1.06 
(-3.56, 1.44) 
-0.77 
(-3.23, 1.67) 
-0.50 
(-2.99, 2.00) 
TRF 96 405 50.51 (9.99) 47.76 (9.38) 
2.69 
(0.59, 4.80) ᶧ 
2.60 
(0.50, 4.69) ᶧ 
2.01 
(-0.19, 4.20) 
2.06 
(-0.08, 4.21) 
3.31 
(1.16, 5.47) ᶧ 
CBCL 109 457 49.32 (10.16) 46.75 (10.46) 
2.53 
(0.37, 4.70) ᶧ 
2.60 
(0.44, 4.76) ᶧ 
1.80 
(-0.47, 4.06) 
1.66 
(-0.54, 3.86) 
2.58 
(0.35, 4.81) ᶧ 
Note:  Adjusted mean differences were adjusted by maternal age, race, education, region, pre-pregnancy BMI, smoking status, drinking 
status; ᶧ p<0.05
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Table 4 
Neurodevelopmental test scores among children whose mothers reported treated infections during early pregnancy compared 
to those children whose mother reported untreated infection during early pregnancy 
 
Test Any Infection URI UGI 
 N Mean (SD) 
Mean Difference 
(95% CI) 
N Mean (SD) 
Mean Difference 
(95% CI) 
N Mean (SD) 
Mean Difference 
(95% CI) 
PPVT-III 303 106.65 (14.39) 
1.90 
(-1.48, 5.28) 
266 106.64 (14.44) 
3.10 
(-0.61, 6.81) 
22 109.77 (12.40) 
-3.42 
(-8.77, 1.92) 
VMI-5 305 96.97 (10.89) 
-0.98 
(-3.64, 1.68) 
267 96.89 (11.03) 
-1.03 
(-3.96, 1.90) 
23 98.26 (11.29) 
1.22 
(-3.52, 5.97) 
TRF 319 49.24 (9.53) 
2.05 
(-0.28, 4.39) 
279 49.58 (9.64) 
2.01 
(-0.55, 4.58) 
26 45.62 (9.19) 
3.45 
(-0.36, 7.26) 
CBCL 360 48.26 (10.48) 
1.92 
(-0.47, 4.31) 
313 48.92 (10.35) 
2.28 
(-0.30, 4.87) 
31 43.55 (11.79) 
0.95 
(-3.63, 5.53) 
Note:  Mean differences were adjusted by maternal age, race, education, region, pre-pregnancy BMI, smoking status, and drinking status 
  
22 
Bibliography 
Achenbach, T., & Rescorla, L. (2001). Manual for the ASEBA School-Age Forms and 
Profiles. Burlington, Vermont: University of Vermont, Research Center for 
Children Youth and Families. 
Amann, U., Egen-Lappe, V., Strunz-Lehner, C., & Hasford, J. (2006, Mar 24). 
Antibiotics in pregnancy: analysis of potential risks and determinant in a large 
German statutory sickness fund population. Pharmacoepidemiology and Drug 
Safety, 15, 327-337. doi:10.1002/pds.1225 
Atladóttir, H. Ó., Henriksen, T. B., Schendel, D. E., & Parner, E. T. (2012, December). 
Autism After Infection, Febrile Episodes, and Antibiotic Use During Pregnancy: 
An Exploratory Study. Pediatrics, 130(6), e1447-e1454. doi:10.1542/peds.2012-
1107 
Beery, K. E., Buktenica, N. A., & Beery, N. A. (2004). Beery-Buktenica Developmental 
Test of Visual-Motor Integration (5th ed.). Minneapolis, Minnesota: NCS 
Pearson. 
Boston University Sloan Drug Dictionary. (n.d.). 
Cenit, M. C., Sanz, Y., & Codoñer-Franch, P. (2017, August 14). Influence of gut 
microbiota on neuropsychiatric disorders. World Journal of Gastroenterology, 
23(30), 5486-5498. doi:10.3748/wjg.v23.i30.5486 
Collett, B. R., Speltz, M. L., Cloonan, Y. K., Lerouz, B. G., Kelly, J. P., & Werler, M. M. 
(2011, February). Neurodevelopmental Outcomes in Children with Hemifacial 
Microsomia. Archives of Pediatrics and Adolecent Medicine, 165(2), 134-140. 
doi:10.1001/archpediatrics.2010.271 
Czeizel, A. E., Rockenbauer, M., & Olsen, J. (1998, June 18). Use of Antibiotics During 
Pregnancy. European Journal of Obstetrics & Gyneocology and Reproductive 
Biology, 81, 1-8. doi:10.1016/S0301-2115(98)00138-9 
Dashe, J. S., & Gilstrap, L. C. (1997, September). Antibiotic use in pregnancy. 
Prescribing in Pregnancy, 24(3), 617-629. 
Dunn, L. M., & Dunn, L. M. (1997). Peabody Picture Vocabulary Test (PPVT-III) (3rd 
ed.). Circle Pines, Minnesota: American Guidance Service. 
Gonzalez-Perez, G., Hicks, A. L., Tekieli, T. M., Radens, C. M., Williams, B. L., & 
Lamouse´-Smith, E. S. (2016, February 26). Maternal Antibiotic Treatment 
Impacts Development of the. The Journal of Immunology (196), 3768-3779. 
doi:10.4049/jimmunol.1502322 
  
23 
Hamad. (2019). Prenatal antibitics exposure and the risk of autism spectrum disorders: A 
populaiton-based cohort study. PLoS ONE, 14(8). 
doi:10.1371/journal.pone.0221921 
Headley, J., Northstone, K., Simmons, H., Golding, J., & ALSPAC Study Team. (2004, 
May 28). Medication use during pregnancy: data from the Avon Longitudinal 
Study of Parents and Children. Pharmacoepidemiology and Prescription, 60, 355-
361. doi:10.1007/s00228-004-0775-7 
Kuperman, A., & Koren, O. (2016). Antibiotic use during pregnancy: how bad is it? BMC 
Medicine, 14(91), 1-7. doi:10.1186/s12916-016-0636-0 
Landers, D. V., Green, J. R., & Sweet, R. L. (1983, Jun 02). Antibiotic use during 
pregnancy and the postpartum period. Clinical Obstetrics and Gynecology, 26(2), 
391-406. 
Lee, Y. H., Papandonatos, G. D., Savitz, A. D., Heindel, W. C., & Buka, S. L. (2020). 
Effects of prenatal bacterial infection on cognitive performance in early 
childhood. Paediatric and Perinatal Epidemiology, 34, 72-81. 
doi:10.1111/ppe.1260 
Martin, J. A., Hamilton, B. E., Osterman, M. J., Driscoll, A. K., & Drake, P. (2018, 
November 07). Births: Final Data for 2017. National Vital Statistics Reports, 
67(8), 1-12. 
Mitchell, A. A., Gilboa, S. M., Werler, M. M., Kelley, K. E., Louik, C., Hernandez-Diaz, 
S., & the National Birth Defects Prevention Study. (2011, July). Medication Use 
During Pregnancy, With Particular Focus On Prescription Drugs: 1976-2008. 
American Journal of Obstetrics and Gynecology, 205(1), e1-51. 
doi:doi:10.1016/j.ajog.2011.02.029 
Parker, S. E., Lijewski, V. A., Janulewicz, P. A., Collett, B. R., Speltz, M. L., & Werler, 
M. M. (2016). Upper respiratory infection during pregnancy and 
neurodevelopmental outcomes among offspring. Neurotoxicology and Teratology, 
57, 54-59. 
Werler, M. M., Sheehan, J. E., Hayes, C., Padwa, B. L., Mitchell, A. A., & Mulliken, J. 
B. (2004, September). Demographic and Reproductive Factors Associated with 
Hemifacial Microsomia. Cleft Palate-Craniofacial Journal, 41(5), 494-500. 
doi:10.1597/03-110.1 
Xiao, D., Zhu, T., Qu, Y., Huang, Q., & Mu, D. (2018). Maternal chorioamnionitis and 
neurodevelopmental outcomes in preterm and very preterm neonates: A meta-
analysis. PLoS ONE, 13(12), 1-14. 
 24 
Curriculum Vitae 
 25 
  
26 
